Altimmune, a clinical-stage biopharmaceutical company in Gaithersburg, Maryland, develops peptide-based therapeutics for obesity and liver diseases, including the lead candidate pemvidutide. The company has completed Phase II trials for both pemvidutide and HepTcell, targeting metabolic dysfunction and hepatitis B.
ALT has been in the news recently: The Schall Law Firm and Gross Law Firm are informing investors about a class action lawsuit against Altimmune, Inc. due to misleading statements that may have affected shareholders between August 10, 2023, and June 25, 2025. Additionally, Levi & Korsinsky, LLP is pursuing legal action following a 53.2% drop in Altimmune's stock, linked to alleged securities fraud during the same period.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
